| __timestamp | BioMarin Pharmaceutical Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 5758000 |
| Thursday, January 1, 2015 | 152008000 | 8423000 |
| Friday, January 1, 2016 | 209620000 | 11986000 |
| Sunday, January 1, 2017 | 241786000 | 15215000 |
| Monday, January 1, 2018 | 315264000 | 15356000 |
| Tuesday, January 1, 2019 | 359466000 | 16660000 |
| Wednesday, January 1, 2020 | 524272000 | 52459000 |
| Friday, January 1, 2021 | 470515000 | 75061000 |
| Saturday, January 1, 2022 | 483669000 | 87221000 |
| Sunday, January 1, 2023 | 577065000 | 83779000 |
| Monday, January 1, 2024 | 580235000 |
Unleashing insights
In the competitive landscape of pharmaceuticals, understanding cost structures is crucial. From 2014 to 2023, BioMarin Pharmaceutical Inc. and Supernus Pharmaceuticals, Inc. have shown distinct trajectories in their cost of revenue. BioMarin's cost of revenue has surged by approximately 345%, reflecting its aggressive expansion and increased production capabilities. In contrast, Supernus Pharmaceuticals has experienced a more modest increase of around 1,355%, indicating a steady growth strategy.
These trends underscore the differing strategies of these companies in navigating the pharmaceutical market, with BioMarin focusing on rapid expansion and Supernus on steady growth.
Cost of Revenue Trends: Amgen Inc. vs Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Zoetis Inc. and Supernus Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs BioMarin Pharmaceutical Inc.
Cost of Revenue Trends: BeiGene, Ltd. vs BioMarin Pharmaceutical Inc.
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs ADMA Biologics, Inc.
Comparing Cost of Revenue Efficiency: BioMarin Pharmaceutical Inc. vs PTC Therapeutics, Inc.
BioMarin Pharmaceutical Inc. vs Ligand Pharmaceuticals Incorporated: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: BioMarin Pharmaceutical Inc. vs Wave Life Sciences Ltd.
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Galapagos NV
Cost of Revenue: Key Insights for Telix Pharmaceuticals Limited and Supernus Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Ligand Pharmaceuticals Incorporated and Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Mesoblast Limited's Expenses